Enanta Pharmaceuticals to Host Conference Call on August 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2022

Rhea-AI Summary

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) is set to announce its financial results for Q3 2022, concluded on June 30, 2022, on August 8, 2022, post-market. A conference call will be held at 4:30 p.m. ET the same day to discuss the results and updates on the company’s R&D pipeline. Enanta focuses on drug discovery for viral infections and liver diseases, including respiratory syncytial virus (RSV) and hepatitis B virus (HBV), while funding is supported by royalties from its collaboration with AbbVie on hepatitis C virus (HCV) treatments.

Positive

• Ongoing development of clinical candidates for various diseases, including RSV, COVID-19, and HBV.
• Funding of R&D activities through royalties from successful HCV product collaboration with AbbVie.

Negative

• None.

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal third quarter ended June 30, 2022 after the U.S. market closes on August 8, 2022. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta’s business, including its research and development pipeline.

Conference Call and Webcast Information
To participate in the live conference call, please dial 833-634-1237 in the U.S. or 412-317-5277 for international callers. No conference identification number is needed for the live call. A replay of the conference call will be available starting at approximately 7:30 p.m. ET on August 8, 2022, through 11:59 p.m. ET on August 22, 2022, by dialing 877-344-7529 in the U.S. or 412-317-0088 for international callers. The access code for the replay is 2895171. A live audio webcast of the call and replay can be accessed by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com.

About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta’s research and development programs include clinical candidates currently in development for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research in human metapneumovirus (hMPV).

Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic HCV infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET^® (U.S.) and MAVIRET^® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220801005187/en/

Media and Investors

Jennifer Viera

617-744-3848

jviera@enanta.com

Source: Enanta Pharmaceuticals, Inc.

FAQ

When will Enanta Pharmaceuticals report Q3 2022 financial results?

Enanta Pharmaceuticals will report its Q3 2022 financial results on August 8, 2022, after the market closes.

What time is the conference call for Enanta Pharmaceuticals' financial results?

The conference call will take place at 4:30 p.m. ET on August 8, 2022.

What diseases is Enanta Pharmaceuticals developing treatments for?

Enanta Pharmaceuticals is developing treatments for respiratory syncytial virus (RSV), COVID-19, and hepatitis B virus (HBV).

How does Enanta Pharmaceuticals fund its R&D activities?

Enanta funds its R&D activities through royalties from hepatitis C virus products developed in collaboration with AbbVie.